Two leaders in the battle against the number one killer in the United States - heart disease -have been appointed co-directors of the Stanford Cardiovascular Institute, the nucleus for research and advancements in clinical care for patients with heart disease here.
In a just-posted online story, it was announced that Joseph Wu, MD, PhD, whose work we have previously written about here, and Robert Harrington, MD, chair of the Department of Medicine, will replace Robert Robbins, MD, who left Stanford in November to head up the Texas Medical Center in Houston.
The new dean of the medical school, Lloyd Minor, MD, is quoted in the story lauding the new appointments for the institute, an interdisciplinary organization that includes 500 Stanford basic scientists and researchers:
These two world-renowned researchers bring a unique expertise that will lead the Cardiovascular Institute into the future. Dr. Wu, as an expert in basic science research, and Dr. Harrington, as a leader in clinical trials and population science, will lead the institute on the path toward translating scientific knowledge to improve cardiovascular health for patients.
